双膦酸盐类药物用于钙化防御治疗的文献分析

梁春苏; 王少红; 张逸舟; 刘鑫; 牛子冉; 史亦丽; 张波

doi:10.12376/j.issn.2097-0501.2024.02.009

双膦酸盐类药物用于钙化防御治疗的文献分析

Literature Review of Using Bisphosphonates in the Treatment of Calciphylaxis

摘要

摘要:
目的分析双膦酸盐类药物用于钙化防御患者治疗的有效性和安全性。
方法检索PubMed、Embase、中国知网及万方数据库，收集报道双膦酸盐用于钙化防御的病例报告，提取患者相关信息进行统计分析。
结果纳入文献共18篇病例报告，患者20例，结果显示13例患者(65.0%)采用帕米膦酸盐治疗，4例患者(20.0%)采用依替膦酸盐，2例患者(10.0%)采用阿仑膦酸盐，1例患者(5.0%)采用唑来膦酸。13例患者(65.0%)完全康复，康复时间为0.5~9个月。大部分患者双膦酸盐类药物的耐受性较好(90.0%)，1例不耐受帕米膦酸盐的患者在调整给药频次后康复，1例依替膦酸盐高给药剂量患者在停用后指标恢复正常。
结论双膦酸盐类药物作为一种骨吸收的抑制剂，兼具有效性和安全性，有望用于钙化防御患者的治疗。

Abstract:
Objective To analyze the effectiveness and safety of bisphosphonates in the treatment of patients with calcification defense.
Methods PubMed, Embase databases, CNKI and Wanfang were searched to collect the case reports and clinical studies of bisphosphonates for calcification defense. Then, the relevant information of patients was extracted for statistical analysis.
Results A total of 18 case reports were selected involving 20 patients. Thirteen patients (65.0%) were treated with pamidronate, four (20.0%) were treated with etidronate, two (10.0%) were treated with alendronate, and one (5.0%) was treated with zoledronic acid. Thirteen patients (65.0%) recovered completely, the recovery time of whom ranged from half month to nine months. The tolerance of bisphosphonates in most patients(90.0%)was good, while one patient who did not tolerate pamidronate recovered after the frequency of administration was adjusted and one patient with high dosage of etidronate returned to normal after the discontinuation of the usage.
Conclusions Bisphosphonates, an inhibitor of bone resorption, is effective and safe in the treatment of patients with calcification defense.

HTML全文

参考文献(29)

施引文献

资源附件(0)